Skip to main content

Home/ Nutrition/ Group items tagged primary_prevention

Rss Feed Group items tagged

Matti Narkia

Welcome to to VITamin D and omegA-3 triaL (VITAL) Web site - 0 views

  •  
    What is VITAL? The VITamin D and OmegA-3 TriaL (VITAL) is a research study in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D (about 2000 IU) or fish oil (about 1 gram of omega-3 fatty acids) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. Recruitment for the study will begin in January 2010.
Matti Narkia

JUPITER: Low LDL and low CRP best for reducing events in primary prevention - theheart.org - 0 views

  •  
    "March 29, 2009 | Michael O'Riordan Orlando, FL - Reducing LDL cholesterol and high-sensitivity C-reactive protein (hs-CRP) in primary-prevention patients treated with rosuvastatin (Crestor, AstraZeneca) results in better event-free survival than when neither of these targets are achieved or when LDL cholesterol alone is reduced, a new analysis shows [1]. Presenting the results of the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study during an afternoon press conference at the American College of Cardiology 2009 Scientific Sessions, investigators say that initial interventions for low-risk primary-prevention patients remains lifestyle and dietary modifications, but for those choosing drug therapy, "reductions in both LDL cholesterol and hs-CRP are indicators of the success of treatment with statin therapy.""
1 - 2 of 2
Showing 20 items per page